What is William Blair’s Estimate for NMRA FY2024 Earnings?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Research analysts at William Blair lowered their FY2024 earnings estimates for Neumora Therapeutics in a report released on Tuesday, November 12th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($1.63) for the year, down from their previous estimate of ($1.48). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.48) per share. William Blair also issued estimates for Neumora Therapeutics’ Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($1.94) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.07). During the same quarter in the prior year, the firm earned ($1.14) EPS.

Several other equities research analysts have also issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a report on Wednesday. JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.67.

Neumora Therapeutics Stock Up 8.5 %

NASDAQ NMRA opened at $11.69 on Friday. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00. The business’s 50-day simple moving average is $13.07 and its 200-day simple moving average is $11.41.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors have recently made changes to their positions in the company. Amalgamated Bank increased its stake in Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after purchasing an additional 2,402 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of Neumora Therapeutics by 35.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock valued at $351,000 after buying an additional 6,900 shares during the last quarter. Quarry LP acquired a new stake in Neumora Therapeutics during the second quarter worth about $98,000. Intech Investment Management LLC bought a new position in Neumora Therapeutics in the third quarter worth about $175,000. Finally, Ballentine Partners LLC acquired a new position in Neumora Therapeutics in the third quarter valued at approximately $178,000. 47.65% of the stock is currently owned by institutional investors.

Insider Activity

In other Neumora Therapeutics news, insider Robert A. Lenz sold 5,563 shares of the firm’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the transaction, the insider now directly owns 322,966 shares of the company’s stock, valued at $4,847,719.66. This trade represents a 1.69 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joshua Pinto sold 28,496 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $11.63, for a total transaction of $331,408.48. Following the completion of the sale, the chief financial officer now owns 210,469 shares in the company, valued at approximately $2,447,754.47. This trade represents a 11.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,538 shares of company stock worth $1,390,513 over the last ninety days. Corporate insiders own 26.40% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.